NCT00006695 2023-09-01
Monoclonal Antibody Therapy, Combination Chemotherapy, and Peripheral Stem Cell Transplant in Non-Hodgkin's Lymphoma
University of Nebraska
Phase 2 Completed
Clinical Trials
22 trialsNCT00479167 2021-11-04
A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma
Rush University Medical Center
Phase 2 Terminated
NCT00329030 2021-11-01
BMTCTN0401
National Heart, Lung, and Blood Institute (NHLBI)
Phase 3 Completed
NCT00777114 2018-08-13
Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy
Weill Medical College of Cornell University
Phase 1 Completed
NCT01536561 2017-08-31
Study of Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas and Extended Study to Determine the Safety and Efficacy of Coulter Clone® 131Iodine-B1 Radioimmunotherapy of Advanced Non-Hodgkin's Lymphoma
GlaxoSmithKline
Phase 1 Completed
NCT00992758 2017-07-25
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Non Hodgkin's Lymphoma (NHL) Patients With Greater Than 25% Bone Marrow Involvement
GlaxoSmithKline
Phase 1 Completed
NCT00490490 2017-03-29
Study of Bexxar <Tositumomab> Combined With External Beam Radiation Therapy
Stanford University
Phase 2 Terminated
NCT00950755 2017-01-18
Study of Iodine 131 Anti B1 Antibody for 1st or 2nd Relapsed Indolent B-Cell Lymphomas or B-Cell Lymphomas That Have Transformed to a More Aggressive Histology
GlaxoSmithKline
Phase 2 Completed
NCT00996996 2017-01-11
Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab) for Previously Untreated, Advanced-stage, Low Grade Non-Hodgkin's Lymphoma
GlaxoSmithKline
Phase 2 Completed
NCT00268983 2017-01-09
Comparison Of Rituximab Versus Tositumomab and Iodine I 131 Tositumomab (BEXXAR® Therapeutic Regimen) For Patients With Relapsed Follicular Non-Hodgkins Lymphoma
GlaxoSmithKline
Phase 3 Completed
NCT00938041 2017-01-09
Retreatment of Patients With Non-Hodgkin's Lymphoma Who Have Previously Responded to Iodine-131 Anti B1 Antibody
GlaxoSmithKline
Phase 2 Completed
NCT00989664 2016-12-13
Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma
GlaxoSmithKline
Phase 2 Completed
NCT01224821 2016-12-12
RIT-II-001
GlaxoSmithKline
Phase 2 Completed
NCT00996593 2016-11-23
Study of Iodine-131 Anti-B1 Antibody for Patients With Non Hodgkin's Lymphoma Who Have Previously Received Rituximab
GlaxoSmithKline
Phase 2 Completed
NCT00434629 2016-08-17
Safety and Efficacy of Bexxar Therapy in the Treatment of Relapsed/Residual B-Cell Lymphoma After Autologous Transplant
University of Pennsylvania
Phase 1 Completed
NCT00319332 2015-04-17
A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen
GlaxoSmithKline
Phase 3 Withdrawn
NCT00073931 2015-02-05
Iodine I 131 Tositumomab Followed by Autologous Stem Cell Transplantation in Treating Older Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00475332 2012-02-15
Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar
University of Florida
Phase 2 Terminated
NCT00062894 2007-09-17
Study of Untreated or Transformed Follicular Non-Hodgkin's Lymphoma With Fission-Derived Iodine I 131 Tositumomab
GlaxoSmithKline
Phase 1/2 Completed
NCT00022906 2005-06-24
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for NHL Patients With Greater Than 25% Bone Marrow Involvement
Corixa Corporation
Phase 1 Unknown
NCT00022932 2005-06-24
Safety and Efficacy of Iodine-131 Anti-B1 Antibody for Intermediate Grade Non-Hodgkin's Lymphoma Following First Line CHOP
Corixa Corporation
Phase 2 Unknown
NCT00022958 2005-06-24
Expanded Access Study of Iodine-131 Anti-B1 Antibody
Corixa Corporation
Phase NA Unknown